We are live on ! Find out more
VP

venBio Partners Portfolio holdings

AUM $281M
1-Year Est. Return 261.03%
This Fund
S&P 500
This Quarter Est. Return
+10.2%
1 Year Est. Return
+261.03%
3 Year Est. Return
+648.19%
5 Year Est. Return
+623.84%
10 Year Est. Return
–
AUM
$323M
AUM Growth
-$110M
Cap. Flow
-$106M
Cap. Flow %
-33%
Top 10 Hldgs %
100%
Holding
8
New
–
Increased
–
Reduced
3
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
VTYX
Ventyx Biosciences
VTYX
+$45.9M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$35.2M
3
AKRO
Akero Therapeutics
AKRO
+$20.3M
4
HRMY icon
Harmony Biosciences
HRMY
+$4.96M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTYX
1
DELISTED
Ventyx Biosciences
VTYX
$114M 35.19%
3,461,536
-1,550,000
-31% -$45.9M
ALXO icon
2
ALX Oncology
ALXO
$273M
$109M 33.89%
9,699,925
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.04B
$57.1M 17.69%
1,035,396
-90,277
-8% -$4.96M
PHVS icon
4
Pharvaris
PHVS
$2.39B
$25.8M 8.01%
2,296,710
– –
IMPL
5
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
$10.3M 3.21%
2,759,791
– –
CINC
6
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$4.71M 1.46%
383,390
-1,478,866
-79% -$35.2M
ELEV
7
DELISTED
Elevation Oncology
ELEV
$1.77M 0.55%
1,866,339
– –
AKRO
8
DELISTED
Akero Therapeutics
AKRO
– –
-596,483
Closed -$20.3M

Similar funds

FFP
Freedom Financial Partners Oakdale, Minnesota $281M AUM 16.89% 1-Year Est. Return
BDA
Borer Denton & Associates Blue Bell, Pennsylvania $280M AUM 7.09% 1-Year Est. Return
PHC
Panoramic Hills Capital Road Town $280M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
SA
SoundView Advisors Olympia, Washington $281M AUM 17.96% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $281M AUM 56.22% 1-Year Est. Return
IP
Investment Partners New Philadelphia, Ohio $281M AUM 20.9% 1-Year Est. Return

venBio Partners's Q4 2022 Portfolio in Review

As of Q4 2022, venBio Partners held 8 positions worth $323M, down 25% from $432M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

venBio Partners withdrew a net $106M in Q4 2022, closing 1 position and reducing 3 holdings. Its most notable exit was Akero Therapeutics, an estimated $20.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • venBio Partners's biggest Q4 2022 reduction was Ventyx Biosciences, cutting an estimated $45.9M.
  • venBio Partners fully exited Akero Therapeutics in Q4 2022, selling an estimated $20.3M.
  • venBio Partners's ten largest holdings make up 100% of its $323M portfolio in Q4 2022.
  • venBio Partners opened 0 new positions and closed 1 in Q4 2022.
  • venBio Partners's portfolio value fell 25% quarter-over-quarter to $323M.

Based on venBio Partners's 13F filing for Q4 2022, filed 14 Feb 2023.